Read by QxMD icon Read

Serotypes pneumococcal

Jihei Cha, Han Wool Kim, Ji Hyen Lee, Soyoung Lee, Kyung-Hyo Kim
Background: Various pneumococcal vaccines have been evaluated for immunogenicity by opsonophagocytic assay (OPA). A multiplexed OPA (MOPA) for 13 pneumococcal serotypes was developed by Nahm and Burton, and expanded to 26 serotypes in 2012. The development of new conjugate vaccines with increased valence has necessitated expanded MOPAs to include these additional serotypes. In this study, we validated this expanded MOPA platform and applied to measure antibodies against 11 additional serotypes (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20B, 22F, and 33F) in human sera...
December 17, 2018: Journal of Korean Medical Science
Els van Westen, Mirjam J Knol, Alienke J Wijmenga-Monsuur, Irina Tcherniaeva, Leo M Schouls, Elisabeth A M Sanders, Cecile A C M van Els, Guy A M Berbers, Nynke Y Rots
The two currently available ten- and thirteen-valent pneumococcal conjugate vaccines (PCV10 and PCV13) both induce serotype-specific IgG anti-polysaccharide antibodies and are effective in preventing vaccine serotype induced invasive pneumococcal disease (IPD) as well as in reducing overall vaccine-serotype carriage and transmission and thereby inducing herd protection in the whole population. IgG levels decline after vaccination and could become too low to prevent carriage acquisition and/or pneumococcal disease...
December 11, 2018: Vaccines
Ricardo U Sorensen, J David M Edgar
Streptococcus pneumoniae (S. pneumoniae) strains colonize the nasopharynx and can cause mucosal infections in the upper airway and middle ear, pneumonias, and invasive infections like bacteremia, sepsis, and meningitis. Over 90 serotypes, defined by the structure of their capsular polysaccharides, are known. Twenty-three of these serotypes cause most infections and several of these serotypes can develop antibiotic resistance. Susceptibility factors that increase the susceptibility to S. pneumoniae mucosal and invasive infections include all forms of primary and secondary antibody deficiencies...
December 2018: Transfusion
María Luisa Rioseco Z, Raúl Riquelme O, Mauricio Riquelme O, Carlos Inzunza P, Javier Riquelme D, Andrea Sanhueza R
BACKGROUND: Bacteremic pneumococcal pneumonia (BPP) is a preventable disease with high morbimortality. AIM: To evaluate clinical aspects and mortality on BPP patients admitted to a Chilean regional hospital. PATIENTS AND METHODS: We looked for adult patients with Streptococcus pneumoniae isolated from blood cultures between 2010 and 2014 years and reviewed clinical records of those who were admitted with pneumonia. RESULTS: We identified 70 BPP patients: 58% were men, mean age was 56 years, 30% were > 65 years, 70% with basic public health insurance, 26% were alcoholics, 86% had comorbidities...
July 2018: Revista Médica de Chile
Win-Yan Chan, Claire Entwisle, Giuseppe Ercoli, Elise Ramos-Sevillano, Ann McIlgorm, Paola Cecchini, Christopher Bailey, Oliver Lam, Gail Whiting, Nicola Green, David Goldblatt, Jun X Wheeler, Jeremy S Brown
Current vaccination against Streptococcus pneumoniae uses vaccines based on capsular polysaccharides from selected serotypes, and has led to non-vaccine serotype replacement disease. We have investigated an alternative serotype-independent approach, using multiple-antigen vaccines (MAV) prepared from S. pneumoniae TIGR4 lysates enriched for surface proteins by a chromatography step after culture under conditions that induce expression of heat shock proteins (Hsp, thought to be immune adjuvants). Proteomics and immunoblots demonstrated that compared to standard bacterial lysates, MAV was enriched with Hsps and contained several recognised protective protein antigens, including pneumococcal surface protein A (PspA) and pneumolysin (Ply)...
December 10, 2018: Infection and Immunity
Wei Shi, Jing Li, Fang Dong, Suyun Qian, Gang Liu, Baoping Xu, Lin Zhou, Wenjian Xu, Qinghong Meng, Qing Wang, Kunling Shen, Lijuan Ma, Kaihu Yao
Invasive pneumococcal disease (IPD) is a serious threat to children worldwide. This study reported the serotype distribution, antibiotic resistance pattern and multilocus sequence types of 111 IPD strains isolated from children less than 14 years old in two tertiary pediatric centers in Beijing during years 2012-2017. Methods Serotypes were determined using Quellung reaction. Antibiotic resistance was tested using the E-test or disc diffusion method. Sequence types (STs) were assigned via multilocus sequence typing...
December 10, 2018: Expert Review of Vaccines
Bernard Beall, Sopio Chochua, Robert E Gertz, Yuan Li, Zhongya Li, Lesley McGee, Benjamin J Metcalf, Jessica Ricaldi, Theresa Tran, Hollis Walker, Tamara Pilishvili
Invasive pneumococcal disease (IPD) has greatly decreased since implementation in the U.S. of the 7 valent conjugate vaccine (PCV7) in 2000 and 13 valent conjugate vaccine (PCV13) in 2010. We used whole genome sequencing (WGS) to predict phenotypic traits (serotypes, antimicrobial phenotypes, and pilus determinants) and determine multilocus genotypes from 5334 isolates (~90% of cases) recovered during 2015-2016 through Active Bacterial Core surveillance. We identified 44 serotypes; 26 accounted for 98% of the isolates...
2018: Frontiers in Microbiology
L Zhu, W H Li, X H Wang, K Tan, Q F Fang, Q X Zhu, K K Wu, Q Z Yang, A W Lin, H L Deng, J Bi, J Liu, S Y Zhao, Y Liu, S J Jing, Y M Wang, L M Li, Q Zhao, K H Yao, X Wang, L Jia, F Wang, J K Deng, J Sun, C H Zhu, K Zhou, J Liang, X Z Nie, S C Cao, D M Wang, S J Li, X X Chen, J Li, Y Wang, L Ye, Y H Zhang, F Dong, Z Li, Y H Yang, G Liu
Objective: To explore the clinical features, the serotype distribution and drug resistance of the isolates in patient with invasive pneumococcal disease (IPD). Methods: By retrieving the laboratory information system in 18 children's hospitals from 2012 to 2017, the children with IPD were enrolled. Streptococcus pneumoniae (Spn) must be isolated from the sterile sites (blood, cerebrospinal fluid, hydrothorax and joint effusion etc.). The clinical characteristics, serotype, drug resistance, treatment and prognosis were reviewed and analyzed...
December 2, 2018: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
Daniel Dalcin, Lee Sieswerda, Sacha Dubois, Marina Ulanova
BACKGROUND: Despite the use of pneumococcal vaccines, indigenous populations are consistently disproportionately affected by invasive pneumococcal disease (IPD). With recent changes in Ontario's provincial pneumococcal vaccination program, we sought to evaluate the epidemiology and burden of IPD in northwestern Ontario (NWO) Canada - a region that contains a substantial (19.2%) indigenous population. METHODS: We retrospectively reviewed all adult cases of IPD that were reported to the Thunder Bay District Health Unit, in Thunder Bay, Ontario, Canada, over a 10-year period (2006-2015)...
December 4, 2018: BMC Infectious Diseases
Zhifeng Chen, Kara S Cox, Aimin Tang, Jeanette Roman, Malorie Fink, Robin M Kaufhold, Liming Guan, Andy Xie, Melissa A Boddicker, Debra Mcguinness, Xiao Xiao, Hualin Li, Julie M Skinner, Thorsten Verch, Mary Retzlaff, Kalpit A Vora
BACKGROUND: Community-acquired pneumonia is a leading infectious cause of hospitalization. A few vaccines exist to prevent pneumococcal disease in adults, including a pneumococcal polysaccharide unconjugated vaccine and a protein conjugated polysaccharide vaccine. Previous studies on the human immune response to the unconjugated vaccine showed that the vaccine boosted the existing memory B cells. In the present study, we investigated the human B cell immune response following pneumococcal polysaccharide conjugate vaccination...
December 4, 2018: BMC Infectious Diseases
Yael Berger, Amos Adler, Ariel Tenenbaum, Assaf Rokney, Diana Averbuch, Galia Grisaru-Soen
AIM: This study examined the impact of the routine pneumococcal conjugate vaccination (PCV) on childhood community-acquired bacteraemia (CAB) and antibiotic resistance patterns in Israeli children. METHODS: Israel added the PCV vaccine to its national immunisation programme in July 2009. We retrospectively analysed the medical records of all patients with CAB under 18 years at three children's hospitals in Tel Aviv and Jerusalem from 2007-2015. The microbiological data, clinical presentation, pneumococcal serotype distribution, antibiotic susceptibility and outcomes of infections were compared before and after the vaccine was introduced...
December 2, 2018: Acta Paediatrica
Annefleur C Langedijk, Mariëlle van Aalst, Bob Meek, Ester M M van Leeuwen, Sacha Zeerleder, Ellen Meijer, Mette D Hazenberg, Martin P Grobusch, Abraham Goorhuis
Infection with Streptococcus pneumoniae is a life-threatening, but vaccine preventable complication in patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The international consensus on post allo-HSCT immunization schedules, starting 3-6 months after HSCT, focuses on short-term immunogenicity while long-term immunogenicity is not well characterized. The current Dutch immunization schedule, which starts at 12 months post allo-HSCT, was developed as a result of concerns on the coverage of long-term immunogenicity in international guidelines...
November 27, 2018: Vaccine
Catherine Satzke, Eileen M Dunne, Molina Choummanivong, Belinda D Ortika, Eleanor F G Neal, Casey L Pell, Monica L Nation, Kimberley K Fox, Cattram D Nguyen, Katherine A Gould, Jason Hinds, Anisone Chanthongthip, Anonh Xeuatvongsa, E Kim Mulholland, Vanphanom Sychareun, Fiona M Russell
Pneumococcal carriage is a prerequisite for disease, and underpins herd protection provided by pneumococcal conjugate vaccines (PCVs). There are few data on the impact of PCVs in lower income settings, particularly in Asia. In 2013, the Lao People's Democratic Republic (Lao PDR) introduced 13-valent PCV (PCV13) as a 3 + 0 schedule (doses at 6, 10 and 14 weeks of age) with limited catch-up vaccination. We conducted two cross-sectional carriage surveys (pre- and two years post-PCV) to assess the impact of PCV13 on nasopharyngeal pneumococcal carriage in 5-8 week old infants (n = 1000) and 12-23 month old children (n = 1010)...
November 27, 2018: Vaccine
Nils Littorin, Fabian Uddén, Jonas Ahl, Fredrik Resman, Hans-Christian Slotved, Simon Athlin, Kristian Riesbeck
Pneumococcal polysaccharide vaccines may elicit a hyporesponse under certain conditions. There is limited knowledge, however, on the type of specific antibody response in individuals with invasive pneumococcal disease (IPD). The aim of this study was to investigate the functional antibody response in patients with IPD caused by different serotypes. Pre-immune and convalescent sera from 40 patients (age 14-91 years) with IPD caused by serotypes with low (serotype 3, 19F, and 23F) and high (1, 4, 7F, and 14) invasive potential were investigated...
2018: Frontiers in Microbiology
Shalom Ben-Shimol, Noga Givon-Lavi, Eugene Leibovitz, David Greenberg, Ron Dagan
BACKGROUND: Complex otitis media (OM) may present with intact tympanic membrane or spontaneous otorrhea. We compared dynamics of intact tympanic membrane and spontaneous otorrhea OM following 7- and 13-valent conjugated vaccines (PCV7, PCV13) implementation, since differences in dynamics may imply different underlying mechanisms. METHODS: A prospective, population-based, active surveillance. Episodes with middle-ear fluid cultures in children < 3 years were included...
November 26, 2018: Vaccine
Ana Paula Cassiolato, Samanta Cristine Grassi Almeida, Ana Lúcia Andrade, Ruth Minamisava, Maria Cristina de Cunto Brandileone
BACKGROUND: In 2010, a ten-valent pneumococcal conjugate vaccine (PCV10) was introduced in the routine infant national immunization program in Brazil. Invasive pneumococcal disease (IPD) caused by serotype 19A (Spn19A) increased after the introduction of PCVs in several countries. We compared the frequency, antimicrobial resistance and molecular patterns of invasive Spn19A strains before and after PCV10 introduction in Brazil using data from the national laboratory-based surveillance...
2018: PloS One
Taj Azarian, Patrick K Mitchell, Maria Georgieva, Claudette M Thompson, Amel Ghouila, Andrew J Pollard, Anne von Gottberg, Mignon du Plessis, Martin Antonio, Brenda A Kwambana-Adams, Stuart C Clarke, Dean Everett, Jennifer Cornick, Ewa Sadowy, Waleria Hryniewicz, Anna Skoczynska, Jennifer C Moïsi, Lesley McGee, Bernard Beall, Benjamin J Metcalf, Robert F Breiman, P L Ho, Raymond Reid, Katherine L O'Brien, Rebecca A Gladstone, Stephen D Bentley, William P Hanage
Streptococcus pneumoniae serotype 3 remains a significant cause of morbidity and mortality worldwide, despite inclusion in the 13-valent pneumococcal conjugate vaccine (PCV13). Serotype 3 increased in carriage since the implementation of PCV13 in the USA, while invasive disease rates remain unchanged. We investigated the persistence of serotype 3 in carriage and disease, through genomic analyses of a global sample of 301 serotype 3 isolates of the Netherlands3-31 (PMEN31) clone CC180, combined with associated patient data and PCV utilization among countries of isolate collection...
November 2018: PLoS Pathogens
Pilar Ciruela, Conchita Izquierdo, Sonia Broner, Carmen Muñoz-Almagro, Sergi Hernández, Carmen Ardanuy, Roman Pallarés, Angela Domínguez, Mireia Jané
BACKGROUND: We studied the impact of 13-valent pneumococcal conjugate vaccine (PCV13) on the incidence of invasive pneumococcal disease (IPD) and serotype distribution in a region with intermediate levels of vaccination (around 64% in children aged <2 years). METHODS: Surveillance data on IPD cases reported by microbiologists participating in the Microbiological Reporting System of Catalonia during 2006-2014 were analysed. We compared estimated incidence rate (IR) ratios for serotypes included in PCV7, PCV10non7, PCV13non10 and non-PCV13 between the PCV7 (2006-2009) and PCV13 periods (2010-2014)...
November 29, 2018: Vaccine
Eszter Kovács, Judit Sahin-Tóth, Adrienn Tóthpál, Katalin Kristóf, Mark van der Linden, Tamás Tirczka, Orsolya Dobay
Young children - the main asymptomatic carriers of pneumococcus - are often the source of pneumococcal infections. PCV13 replaced PCV7 in 2010 in Hungary and it became a mandatory vaccine in 2014. In this work we surveyed the effect of vaccination in three groups: in healthy children under 7 years; in children of the same age but infected with pneumococcus (P1); in older patients (P2) who were very likely not vaccinated. Nasal swabs were taken from 522 healthy children to screen pneumococcal carriage between March 2015 and May 2016...
November 20, 2018: Vaccine
Se-Jin Kim, Seung Han Seon, Truc Thanh Luong, Prachetash Ghosh, Suhkneung Pyo, Dong-Kwon Rhee
Streptococcus pneumoniae is a well-known pathogenic bacterium with a high mortality rate. Currently, a 23-valent pneumococcal polysaccharide vaccine (PPV23) and protein-conjugate vaccines (PCVs) are available on the market. However, both of these vaccines have limitations; specifically, PPV23 produces weak antibody responses in children younger than 2 years and PCVs only partially protect against secondary infection. Previously, we showed serotype-nonspecific protection by Δpep27 vaccine, but the reversion of Δpep27 to the wild type serotype during immunization cannot be excluded...
November 19, 2018: Vaccine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"